Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening

doi:10.1517/17460441.2010.524640

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药物发现与设计中心

	Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening
	Li, Ning 1; Thompson, Scott 2; Jiang, Hualiang1 ; Lieberman, Paul M.2; Luo, Cheng1,3
刊名	EXPERT OPINION ON DRUG DISCOVERY
	2010-12
卷号	5 期号:12 页码:1189-1203
ISSN号	1746-0441
DOI	10.1517/17460441.2010.524640
文献子类	Review
英文摘要	Areas covered in this review: In this review, we discuss the existing anti-EBV inhibitors and those under development. We discuss the value of different molecular targets, including EBV lytic DNA replication enzymes as well as proteins that are expressed exclusively during latent infection, such as EBV nuclear antigen 1 (EBNA-1) and latent membrane protein 1. As the atomic structure of the EBNA-1 DNA binding domain has been described, it is an attractive target for in silico methods of drug design and small molecule screening. We discuss the use of computational methods that can greatly facilitate the development of novel inhibitors and how in silico screening methods can be applied to target proteins with known structures, such as EBNA-1, to treat EBV infection and disease. What the reader will gain: The reader is familiarized with the problems in targeting of EBV for inhibition by small molecules and how computational methods can greatly facilitate this process. Take home message: Despite the impressive efficacy of nucleoside analogs for the treatment of herpesvirus lytic infection, there remain few effective treatments for latent infections. As EBV latent infection persists within and contributes to the formation of EBV-associated cancers, targeting EBV latent proteins is an unmet medical need. High-throughput in silico screening can accelerate the process of drug discovery for novel and selective agents that inhibit EBV latent infection and associated disease.
资助项目	National Natural Science Foundation of China[00000000] ; State Key Program of Basic Research of China[00000000] ; State Key Laboratory of Drug Research[00000000] ; Shanghai Committee of Science and Technology[00000000] ; Guangdong Science and Technology Department[00000000] ; NIH[R21NS063905]
WOS关键词	HERPES-SIMPLEX-VIRUS ; ENCODED PROTEIN-KINASE ; LYMPHOCYTE GROWTH TRANSFORMATION ; ORIGIN-BINDING PROTEIN ; ORAL HAIRY LEUKOPLAKIA ; IMMORTALIZED B-CELLS ; HUMAN CYTOMEGALOVIRUS ; ANTIVIRAL ACTIVITY ; BURKITTS-LYMPHOMA ; CRYSTAL-STRUCTURE
WOS研究方向	Pharmacology & Pharmacy
语种	英语
出版者	TAYLOR & FRANCIS LTD
WOS记录号	WOS:000284417600005
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/278704]
专题	药物发现与设计中心中科院受体结构与功能重点实验室新药研究国家重点实验室
通讯作者	Li, Ning
作者单位	1.Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, State Key Lab Drug Res, Shanghai 201203, Peoples R China; 2.Wistar Inst Anat & Biol, Philadelphia, PA 19106 USA; 3.Soochow Univ, Ctr Syst Biol, Suzhou 215006, Jiangsu, Peoples R China
推荐引用方式 GB/T 7714	Li, Ning,Thompson, Scott,Jiang, Hualiang,et al. Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening[J]. EXPERT OPINION ON DRUG DISCOVERY,2010,5(12):1189-1203.
APA	Li, Ning,Thompson, Scott,Jiang, Hualiang,Lieberman, Paul M.,&Luo, Cheng.(2010).Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening.EXPERT OPINION ON DRUG DISCOVERY,5(12),1189-1203.
MLA	Li, Ning,et al."Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening".EXPERT OPINION ON DRUG DISCOVERY 5.12(2010):1189-1203.